Italy's AI Law establishes new criminal offenses, creating meaningful risks for US executives and employees. The law ...

Lilly will make its Zepbound KwikPen (tirzepatide) – which delivers four weekly injections in one device – available through the programme at a cost of $449 across all doses for an individual patient, ...

Shares in PepGen were down more than 21% after the FDA placed a partial clinical hold on its lead drug PGN-EDODM1, for rare ...

They found that after three years of follow-up, the group taking GLP-1 agonists like Novo Nordisk's semaglutide and Eli Lilly's tirzepatide were 14% less likely to develop substance use disorders ...

What emerged through such discussions was not optimism nor was it pessimism, but clarity. The consensus was striking in its consistency across sessions. JPM 2026 signalled genuine recovery – but not ...

Hansa had asked the FDA to consider a priority review of its biologics licensing application (BLA) for imlifidase, which was ...

Cardiff, Wales-based Antiverse's computational platform has been set up to find antibodies against challenging drug targets, ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 agonist therapies in the US, promising to slash the monthly cost of its ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

The life sciences are entering a decisive new phase. Over the past decade, artificial intelligence (AI) has proven its value as a powerful tool, helping researchers analyse vast datasets, surface ...

The study analysed two years of search ads linked to Ozempic.com. An estimated $7.5m was spent on 15,000+ keywords, ...

The latest phase of the long-running scheme – run by Cancer Research UK (CRUK) and the National Cancer Institute (NCI) in the ...